Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -27.16% | -9.74% | -12.85% | -18.80% | -32.29% |
| Total Depreciation and Amortization | 110.98% | 133.02% | 101.05% | 134.26% | 74.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.65% | 21.05% | 27.34% | 40.99% | 60.00% |
| Change in Net Operating Assets | 2,315.57% | -87.85% | -49.41% | -189.70% | 94.08% |
| Cash from Operations | -15.69% | -157.40% | -22.37% | -26.97% | -17.02% |
| Capital Expenditure | 231.09% | -2.66% | -22.30% | -24.72% | -16.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.28% | -57.42% | 118.03% | 252.58% | -712.38% |
| Cash from Investing | 55.15% | -59.88% | 127.07% | 273.16% | -731.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 100,344.30% | -99.99% | -92.59% | -92.89% | 22.13% |
| Repurchase of Common Stock | -- | -24.53% | -57.85% | -113.13% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100,259.40% | -100.07% | -288.64% | -808.05% | 22.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.87% | -103.96% | 201.62% | 258.79% | -4,145.03% |